TMO · Thermo Fisher Scientific Inc.
$491.462026-05-17Sector: Healthcare; Industry: Medical - Diagnostics & Research; Sub-Industry: Life Sciences Tools & Services
Intrinsic Value Range Comparison · Mulya.ai
Base · active
$243
-50.5% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($173 · $327) Analysts Range ($575 · $750) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2021.Q4 | $39.2B | — | 26.3% | 12.5% | $9.0B | −$20.9B | −$11.9B | 7.2% | — | 12.7% | $71.3B | $20.49 | — |
| 2022.Q4 | $44.9B | 14.5% | 19.0% | 9.2% | $7.7B | $68MM | $7.8B | 8.3% | — | 10.9% | $70.2B | $18.44 | — |
| 2023.Q4 | $42.9B | -4.6% | 17.4% | 4.6% | $7.1B | −$2.3B | $4.8B | 8.2% | — | 9.9% | $73.8B | $15.90 | — |
| 2024.Q4 | $42.9B | 0.1% | 17.9% | 9.4% | $6.9B | −$1.8B | $5.2B | 8.7% | — | 9.3% | $75.5B | $16.80 | — |
| 2025.Q4 | $44.6B | 3.9% | 18.0% | 7.5% | $7.4B | −$2.3B | $5.1B | 8.7% | — | 9.3% | $83.0B | $17.81 | 23.2 |
| italics below = DCF projection · 10yr Rev CAGR: 5.2% |
| 2026.Q4 | $46.9B | +5.2% | 18.3% | 8.8% | $7.8B | −$1.8B | $6.0B | 9.2% | $5.5B | 9.3% | $84.8B | $20.76 | 23.7 |
| 2027.Q4 | $49.2B | +5.1% | 19.1% | 10.0% | $8.4B | −$2.3B | $6.1B | 9.2% | $5.1B | 9.8% | $87.1B | $22.40 | 21.9 |
| 2028.Q4 | $52.6B | +6.7% | 19.4% | 11.3% | $9.0B | −$4.2B | $4.8B | 9.1% | $3.7B | 10.1% | $91.3B | $24.00 | 20.5 |
| 2029.Q4 | $55.6B | +5.9% | 20.4% | 12.5% | $9.9B | −$2.4B | $7.5B | 9.1% | $5.3B | 10.7% | $93.7B | $26.29 | 18.7 |
| 2030.Q4 | $58.8B | +5.6% | 20.4% | 13.8% | $10.3B | −$2.6B | $7.7B | 9.0% | $5.0B | 10.9% | $96.3B | $27.36 | 18.0 |
|
| Term. Yr+ | $76.9B | 4.1% | 19.6% | 20.0% | $12.0B | −$3.8B | $8.3B | 8.6% | $77.9B | 13.1% | — | — | — |
Active scenario IV: $243 (-50.5% vs market)